Instruction for use: Afala

Dosage form: lozengers

ATX

G04CX Drugs for the treatment of benign prostatic hypertrophy others

Pharmacological group:

Prostate hyperplasia is a benign treatment tool [Other immunomodulators]

The nosological classification (ICD-10)

N39.4 Other specified incontinence: Urinary incontinence; Bed-wetting; Frequent nocturnal urination; Urinary incontinence in women; Anishuriya; Primary bedwetting; Primary nocturnal enuresis in children

N40 Hyperplasia of prostate gland: Prostate adenoma; BPH; Prostatauxe; prostate Hypertrophy; Dysuric disorders caused by benign prostatic hyperplasia; Dizuricheskie disorder with benign prostatic hyperplasia; Dysuria with prostate cancer; Benign prostatic giperpalaziya; Benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2; Benign prostatic hyperplasia I degree; Benign prostatic hyperplasia II degree; Benign prostatic hypertrophy; The disease of the prostate gland; Acute urinary retention related to benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2 in combination with prostatitis; paradoxical ischuria

N41.0 Acute prostatitis: Acute bacterial prostatitis; Urethroprostatitis; Chlamydial prostatitis

N41.1 Chronic prostatitis: Recurrent prostatitis; Chronic bacterial prostatitis; Chronic abacterial prostatitis; Chronic bacterial prostatitis; Chlamydial prostatitis; Exacerbation of chronic prostatitis; Chronic abacterial prostatitis

R30.0 Dysuria: Disorders after prostatectomy; dysuric disorder; Dysuric disorders caused by benign prostatic hyperplasia; dysuric symptoms; dizuricheskie disorder; Dizuricheskie disorder in men; Dysuria with prostate cancer; disorders of urination; dysuria; Dizuricheskie disorder with benign prostatic hyperplasia; Acute dysuria

R39.1 Other difficulties with micturition: Frequent urination; urinary retention; strangury; Obstructed flow of urine; Violation of urination; Violation of urination; Violation of bladder emptying; Violation of the outflow of urine; Frequent urination; Abnormalities of urination

Composition

Tablets for resorption 1 table.

active substance: Antibodies to PSA affinity purified * 0,003 g

Auxiliary substances: lactose monohydrate (lactose) - 0.267 g; MCC - 0.03 g; Magnesium stearate - 0.003 g

* Apply to lactose in the form of a water-alcohol mixture with a content of no more than 10-15 ng / g of the active form of the active substance

Description of dosage form

Tablets are flat-cylindrical, with a risk and chamfer, from white to almost white. On the side with the risk is inscribed "MATERIA MEDICA", on the other - "AFALA".

Pharmachologic effect

Mode of action - immunomodulating.

Pharmacodynamics

Reduces the phenomenon of edema and inflammation in the prostate gland, normalizes its functional state. Improves urodynamics, reduces the volume of residual urine, normalizes the tone of the lower parts of the urinary tract, helps reduce dysuric disorders.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to estimate the content of ultra-small doses of antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of Afala.

Indication of the Afala

Benign prostatic hyperplasia of the I and II stages;

Acute and chronic prostatitis;

In the complex therapy of acute and chronic prostatitis (as an anti-inflammatory and anesthetic agent);

Dysuric disorders (frequent urination, including nocturnal, difficulty urinating, pain or discomfort in the perineum), incl. Accompanying benign prostatic hyperplasia of the I and II stages.

Contraindications

Increased individual sensitivity to the components of the drug.

Side effects

When using the drug for the indicated indications and in the indicated dosages, side effects were not revealed.

Interaction

Cases of incompatibility with other drugs have not been recorded so far.

Dosing and Administration

Inside, not during a meal. According to 2 tables. At the reception (keep the pill in your mouth until completely dissolved). The drug should be taken twice a day, in the morning and in the evening (after and before sleep). The recommended duration of the drug is 16 weeks.

At the expressed painful syndrome and dysuric disturbances in the first 2-3 weeks of therapy the reception of a preparation is shown up to 4 times a day.

If necessary, on the recommendation of a doctor, a repeat course of treatment can be performed after 1-4 months.

Overdose

In case of an accidental overdose, dyspeptic events due to the excipients included in the formulation are possible.

Special instructions

The composition of the drug includes lactose, and therefore it is not recommended to appoint patients with congenital galactosemia, glucose malabsorption syndrome or galactose, or with congenital lactase insufficiency.

The effect of the drug on the ability to drive vehicles or work with other potentially dangerous mechanisms. Does not affect.

Release form

Lozenges. For 20 tablets. In a planar cell packaging made of PVC film and aluminum foil. For 1, 2 or 5 contour squares are placed in a pack of cardboard.

Manufacturer

OOO NPF Materia Medica Holding. Russia, Moscow

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Afala

At temperatures not higher than 25 ° C, in the original packaging.

Keep out of the reach of children.

Shelf life of the drug Afala

3 years.

Do not use after the expiry date printed on the package.